标题
Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014)
作者
关键词
-
出版物
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 25, Issue 9, Pages 953-970
出版商
Informa Healthcare
发表日期
2015-07-10
DOI
10.1517/13543776.2015.1045414
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
- (2015) Marion Peyressatre et al. Cancers
- A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine
- (2015) Elisabeth Walsby et al. Oncotarget
- Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73
- (2015) Frankie Lam et al. Oncotarget
- Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
- (2014) Jian Kang et al. BMC CANCER
- CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
- (2014) Chun-Hao Huang et al. GENES & DEVELOPMENT
- Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles
- (2014) Yang Liu et al. JOURNAL OF CONTROLLED RELEASE
- Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
- (2014) Gaëlle Mariaule et al. MOLECULES
- Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
- (2014) Nicholas Kwiatkowski et al. NATURE
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Targeting cyclin-dependent kinases in anti-neoplastic therapy
- (2013) Céline Bruyère et al. CURRENT OPINION IN CELL BIOLOGY
- Cdks, cyclins and CKIs: roles beyond cell cycle regulation
- (2013) S. Lim et al. DEVELOPMENT
- A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors
- (2013) Tomáš Gucký et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance
- (2013) C. Haider et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres
- (2012) Radek Jorda et al. CURRENT PHARMACEUTICAL DESIGN
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies
- (2011) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
- (2011) K C Goh et al. LEUKEMIA
- Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
- (2011) T. J. Guzi et al. MOLECULAR CANCER THERAPEUTICS
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
- (2010) Clara Albanese et al. MOLECULAR CANCER THERAPEUTICS
- A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
- (2009) Edwina N. Scott et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
- (2009) J. J. Molenaar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
- (2008) Nicholas C Turner et al. EMBO JOURNAL
- Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen
- (2008) A. Bommi-Reddy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started